Retractable Technologies, Inc

Retractable Technologies Inc. designs and manufactures safety-engineered injection devices, including syringes and needles, for healthcare use. The company serves domestic and international customers from the United States and also sources some finished goods through manufacturing arrangements in China.

−35,0 %

0,1 %

−32,8 %

+15,8 %

6.57

4.78

— Retractable Technologies, Inc
%
Safety syringes55% Injection syringes used for vaccination and general medical administration, including domestic production.
Needles and sharps products20% Needles and related safety-engineered sharps products sold to healthcare customers.
EasyPoint® products15% EasyPoint® safety needle products used in healthcare settings and retail pharmacy channels.
International sales10% Products sold to overseas customers, including some shipments sourced from China.

The company sells primarily into healthcare distribution channels, including general line distributors and retail...

  • General line distributorsprimary

    Buy syringes and needles for resale into healthcare supply chains and manage inventory based on demand.

  • Retail pharmacy customerssecondary

    Buy EasyPoint® products for vaccination and flu-season use, where seasonal demand can be important.

  • Vaccination program customersprimary

    Purchase syringes and related products for immunization campaigns and public health use.

  • International healthcare customerssecondary

    Buy selected syringe and needle products, including discounted EasyPoint® sales in some markets.

Retractable Technologies is based in the United States, where it also manufactures a meaningful portion of its products...

  • United States is the core manufacturing and domestic sales base
  • International sales contribute to revenue and product mix
  • Some finished goods are sourced from China under supply arrangements
  • Direct shipments from China to customers affect inventory and logistics
  • Tariffs materially affect both domestic manufacturing economics and imports

The company’s strategic focus is to expand domestic manufacturing capacity and reduce reliance on imported finished...

01
Increase domestic manufacturingshort-term

Reduces dependence on imported supply and supports tariff-sensitive products.

02
Optimize product mixmedium-term

Syringes and EasyPoint® products can support better pricing and demand patterns.

03
Preserve liquidityshort-term

Operations, tariffs, and capital spending require flexible funding sources.

The business is exposed to tariff policy, supply-chain disruption, and the cost of shifting more production into the...

high

Tariffs on China-imported products

Imported syringes, needles, and other products are exposed to high tariff rates.

Scope
Products sourced from China
Materiality
high
high

Distributor inventory overhang

Customers may hold excess vaccination inventory, reducing reorder demand.

Scope
Domestic syringe sales
Materiality
high
high

Manufacturing transition risk

Moving production domestically requires equipment, molds, and workforce ramp-up.

Scope
U.S. manufacturing operations
Materiality
high
medium

Seasonal and vaccination demand swings

Flu season and public acceptance of vaccinations drive volume variability.

Scope
Syringes and EasyPoint® products
Materiality
medium
medium

Rebate and inventory reserve estimation

Distributor rebates and inventory-related write-offs depend on judgment and assumptions.

Scope
Accounts payable and cost of sales
Materiality
medium
Customer rebate reserves
Can materially affect accounts payable and net income
Inventory valuation and write-offs
Affects cost of manufactured product and gross margin
Fair value of debt and equity securities
Affects net income and operating cash flow reconciliation
Tariff-related cost capitalization/expense
Raises cost of sales and reduces reported margins

: 29/04/2026